IVA
Inventiva S.A. (NASDAQ)
Healthcare — Biotechnology
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
Price History
Fundamentals
| Market Cap | $871.65M |
| P/E Ratio (TTM) | - |
| Forward P/E | -4.20 |
| EPS (TTM) | $-2.16 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | -89.90% |
| ROE | - |
| Debt/Equity | - |
| Recommendation | Strong Buy 1.2 |
| Analyst Target | $15.13 |
| Analysts | 13 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 47.1 |
| Beta | 0.88 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $7.98 |
| 52-Week Low | $2.85 |
| 50-Day Avg | $4.61 |
| 200-Day Avg | $5.19 |
| Avg Volume | 673.7K |
| Volume | $1.71M |
Performance Analysis
NEUTRALIVA presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:16 UTC
Back to Screener Export Report